It was a decision a long time in the making, but the Food and Drug Administration has officially given Portola Pharmaceuticals' (NASDAQ: PTLA)AndexXa the green light. The approval ends a winding road for the company that includes a regulatory rejection, a refiling for approval, and requests for additional information.
With a go-ahead finally secured, is this biotech about to become a top stock to buy?Portola Takes Another Big Step Forward
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться